J&J's Doxil manufacturer, Ben Venue, halts production
This article was originally published in Scrip
Executive Summary
Ben Venue, an Ohio-based CMO and Boehringer Ingelheim subsidiary, is temporarily halting production and distribution, citing overdue preventative maintenance and requalification of some equipment. The measure will compound global shortages of J&J's anti-cancer Doxil/Caelyx (doxorubicin HCl liposome injection) which is manufactured at the plant.